BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38591109)

  • 1. Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy.
    Kim D; Kim S; Song H; Gwak D; Min S; Byun JM; Koh Y; Hong J; Yoon SS; Yun H; Shin DY
    Cancer Med; 2024 Apr; 13(7):e7182. PubMed ID: 38591109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution of acute leukemia genomes.
    Jan M; Majeti R
    Oncogene; 2013 Jan; 32(2):135-40. PubMed ID: 22349821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
    Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
    Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of heterogeneity and evolution of subclones in t(8;21) AML by QM-FISH].
    Wang YC; Hu LP; Lin D; Li CW; Yuan T; Jia YJ; Tian Z; Tang KJ; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):844-50. PubMed ID: 24171957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
    Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
    Elife; 2024 Apr; 13():. PubMed ID: 38647535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.
    Kawashima N; Ishikawa Y; Kim JH; Ushijima Y; Akashi A; Yamaguchi Y; Hattori H; Nakashima M; Ikeno S; Kihara R; Nishiyama T; Morishita T; Watamoto K; Ozawa Y; Kitamura K; Kiyoi H
    Nat Commun; 2022 Mar; 13(1):1624. PubMed ID: 35338146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines can reduce clonal, CD34-positive cells in acute myeloid leukemia in vitro.
    Braun S; Gerhartz HH; Schmetzer HM
    Ann Hematol; 2000 Jul; 79(7):363-73. PubMed ID: 10965784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression.
    Kim T; Yoshida K; Kim YK; Tyndel MS; Park HJ; Choi SH; Ahn JS; Jung SH; Yang DH; Lee JJ; Kim HJ; Kong G; Ogawa S; Zhang Z; Kim HJ; Kim DD
    Leukemia; 2016 Feb; 30(2):295-302. PubMed ID: 26424407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH
    Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
    Chao MP; Gentles AJ; Chatterjee S; Lan F; Reinisch A; Corces MR; Xavy S; Shen J; Haag D; Chanda S; Sinha R; Morganti RM; Nishimura T; Ameen M; Wu H; Wernig M; Wu JC; Majeti R
    Cell Stem Cell; 2017 Mar; 20(3):329-344.e7. PubMed ID: 28089908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of bone marrow culture.
    Moore MA
    Hamatol Bluttransfus; 1976; 19():79-90. PubMed ID: 795748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis.
    Pettersson L; Chen Y; George AM; Rigo R; Lazarevic V; Juliusson G; Saal LH; Ehinger M
    Leuk Lymphoma; 2020 Sep; 61(9):2168-2179. PubMed ID: 32425124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia.
    Bochtler T; Stölzel F; Heilig CE; Kunz C; Mohr B; Jauch A; Janssen JW; Kramer M; Benner A; Bornhäuser M; Ho AD; Ehninger G; Schaich M; Krämer A
    J Clin Oncol; 2013 Nov; 31(31):3898-905. PubMed ID: 24062393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal architecture of secondary acute myeloid leukemia.
    Walter MJ; Shen D; Ding L; Shao J; Koboldt DC; Chen K; Larson DE; McLellan MD; Dooling D; Abbott R; Fulton R; Magrini V; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Fan X; Grillot M; Witowski S; Heath S; Frater JL; Eades W; Tomasson M; Westervelt P; DiPersio JF; Link DC; Mardis ER; Ley TJ; Wilson RK; Graubert TA
    N Engl J Med; 2012 Mar; 366(12):1090-8. PubMed ID: 22417201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.
    Mopin A; Leprêtre F; Sebda S; Villenet C; Ben Khoud M; Figeac M; Quesnel B; Brinster C
    PLoS One; 2022; 17(4):e0267508. PubMed ID: 35486629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal evolution of acute myeloid leukemia from diagnosis to relapse.
    Vosberg S; Greif PA
    Genes Chromosomes Cancer; 2019 Dec; 58(12):839-849. PubMed ID: 31478278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
    Ediriwickrema A; Aleshin A; Reiter JG; Corces MR; Köhnke T; Stafford M; Liedtke M; Medeiros BC; Majeti R
    Blood Adv; 2020 Mar; 4(5):943-952. PubMed ID: 32150611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.
    Hackl H; Astanina K; Wieser R
    J Hematol Oncol; 2017 Feb; 10(1):51. PubMed ID: 28219393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.